NCT04464226 2026-04-15
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
Bayer
Phase 3 Active not recruiting
Clinical Trials
60 trialsNCT04958239 2026-04-14
A Study to Test BI 765179 Alone and in Combination With Ezabenlimab in Patients With Advanced Cancer (Solid Tumors) and BI 765179 in Combination With Pembrolizumab in Patients With Advanced Head and Neck Cancer
Boehringer Ingelheim
Phase 1 Active not recruiting
NCT05611632 2026-04-14
NHS-Galleri
GRAIL, Inc.
Phase NA Active not recruiting
NCT02908906 2026-04-13
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of JNJ-63723283, an Anti-PD-1 Monoclonal Antibody, in Participants With Advanced Cancers
Janssen Research & Development, LLC
Phase 1/2 Active not recruiting
NCT03148418 2026-04-13
A Study in Participants Previously Enrolled in a Genentech- and/or F. Hoffmann-La Roche Ltd-Sponsored Atezolizumab Study (IMbrella A)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT04606381 2026-04-13
PALOMA
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05155605 2026-04-13
PATHFINDER 2: A Multi-Cancer Early Detection Study
GRAIL, Inc.
Phase NA Active not recruiting
NCT05993299 2026-04-08
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
Phase 2 Active not recruiting
NCT06703346 2026-04-08
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
USWM, LLC (dba US WorldMeds)
Phase 2 Active not recruiting
NCT05975073 2026-04-07
A Phase 1/2 Study of Anvumetostat in Combination With IDE397 in Participants With Advanced Methylthioadenosine Phosphorylase (MTAP)-Null Solid Tumors
Amgen
Phase 1/2 Active not recruiting
NCT05112965 2026-04-06
An Extension Study in Participants Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study (IMbrella C)
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT05261399 2026-04-06
SAFFRON
AstraZeneca
Phase 3 Active not recruiting
NCT05629234 2026-04-06
ROSY-T
AstraZeneca
Phase 3 Active not recruiting
NCT02584933 2026-04-02
Roll-over Study to Allow Access to Certinib (LDK378) for Patients Who Are on Ceritinib Treatment in a Novartis-sponsored Study
Novartis
Phase 4 Active not recruiting
NCT06018753 2026-04-02
Polaris
Tempus AI
Active not recruiting
NCT04639219 2026-03-23
DPT01
AstraZeneca
Phase 2 Active not recruiting
NCT04419532 2026-03-20
A Study Evaluating DS-1055a in Participants With Relapsed or Refractory Locally Advanced or Metastatic Solid Tumors
Daiichi Sankyo
Phase 1 Active not recruiting
NCT00750841 2026-02-23
Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours
AstraZeneca
Phase 1 Active not recruiting
NCT05396833 2026-02-19
Study of Tuvusertib (M1774) in Combination With DNA Damage Response Inhibitor or Immune Checkpoint Inhibitor (DDRiver Solid Tumors 320)
EMD Serono
Phase 1 Active not recruiting
NCT04078295 2026-02-10
A Study of E7389 Liposomal Formulation (E7389-LF) Plus Nivolumab in Participants With Solid Tumor
Eisai Inc.
Phase 1/2 Active not recruiting
NCT03260023 2026-02-05
Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers
Transgene
Phase 1/2 Active not recruiting
NCT06077877 2026-02-02
A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors
GlaxoSmithKline
Phase 1/2 Active not recruiting
NCT03964727 2026-01-30
TROPiCS-03
Gilead Sciences
Phase 2 Active not recruiting
NCT04170153 2026-01-30
Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)
EMD Serono
Phase 1 Active not recruiting
NCT03768063 2026-01-29
IMbrella B
Hoffmann-La Roche
Phase 3 Active not recruiting
NCT03096093 2026-01-20
Investigation of a Therapeutic Vaccine (ACIT-1) in Cancer
Cancer Vaccines Limited
Phase 1/2 Active not recruiting
NCT00781612 2025-12-24
A Safety Extension Study of Trastuzumab Emtansine in Participants Previously Treated With Trastuzumab Emtansine Alone or in Combination With Other Anti-Cancer Therapy in One of the Parent Studies
Genentech, Inc.
Phase 2 Active not recruiting
NCT05731271 2025-12-17
A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors
Suzhou Transcenta Therapeutics Co., Ltd.
Phase 1/2 Active not recruiting
NCT06107413 2025-12-12
Study to Assess Adverse Events and Change in Disease Activity in Previously Treated Adult Participants Receiving Intravenous (IV) ABBV-400 With Unresectable Metastatic Colorectal Cancer in Combination With IV Fluorouracil, Folinic Acid, and Bevacizumab
AbbVie
Phase 2 Active not recruiting
NCT04898543 2025-12-11
QUILT-3.076: Study of Autologous M-CENK in Subjects With Locally Advanced or Metastatic Solid Tumors
ImmunityBio, Inc.
Phase 1 Active not recruiting
NCT04452955 2025-12-02
A Study to Assess Safety and Efficacy of PRL3-Zumab in Patients With Solid Tumors
Intra-IMMUSG Pte Ltd
Phase 2 Active not recruiting
NCT05205967 2025-11-26
REFLECTION: A Clinical Practice Learning Program for Galleri®
GRAIL, Inc.
Active not recruiting
NCT04214288 2025-11-20
SERENA-2
AstraZeneca
Phase 2 Active not recruiting
NCT00463814 2025-11-13
AZD6244 (ARRY-142886) Solid Oral Dosage Formulation in Participants With Advanced Solid Malignancies
AstraZeneca
Phase 1 Active not recruiting
NCT04446351 2025-10-27
Study of the Safety and Effectiveness of GSK6097608 in Participants With Advanced Solid Tumors
GlaxoSmithKline
Phase 1 Active not recruiting
NCT05898399 2025-10-15
Study of ART6043 in Advanced/Metastatic Solid Tumors Patients
Artios Pharma Ltd
Phase 1/2 Active not recruiting
NCT05374915 2025-08-28
Efficacy and Safety Study of REM-001 Photodynamic Therapy for Treatment of Cutaneous Metastatic Breast Cancer (CMBC)
Kintara Therapeutics, Inc.
Phase 2 Active not recruiting
NCT02099058 2025-08-14
A Study Evaluating the Safety, Pharmacokinetics (PK), and Preliminary Efficacy of ABBV-399 in Participants With Advanced Solid Tumors
AbbVie
Phase 1 Active not recruiting
NCT05717348 2025-08-13
A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours
Elpiscience Biopharma, Ltd.
Phase 1 Active not recruiting
NCT06547957 2025-08-13
A First-in-Human Study of EOS301984 as Monotherapy or Combination Therapy in Adult Participants With Advanced Solid Tumors
iTeos Therapeutics
Phase 1 Active not recruiting
NCT02671435 2025-07-22
A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors
MedImmune LLC
Phase 1/2 Active not recruiting
NCT03415035 2025-07-16
VERONE
AbbVie
Active not recruiting
NCT06980454 2025-07-08
Phase I PK Comparison of HLX05 vs. Erbitux® in Healthy Chinese Males: Safety, Immunogenicity, and Pharmacokinetics
Shanghai Henlius Biotech
Phase 1 Active not recruiting
NCT04648202 2025-06-27
FS120 Phase 1/1b Study in Patients With Advanced Malignancies
invoX Pharma Limited
Phase 1 Active not recruiting
NCT02637687 2025-06-22
SCOUT
Bayer
Phase 1/2 Active not recruiting
NCT04976634 2025-04-06
MK-6482-016
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT04401020 2025-03-21
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL
Sanofi
Phase 1 Active not recruiting
NCT05862324 2025-02-14
TACTIC-3
Triumvira Immunologics, Inc.
Phase 1/2 Active not recruiting
NCT04050436 2025-01-27
CERPASS
Replimune Inc.
Phase 2 Active not recruiting
NCT04130542 2024-10-31
Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Keytruda (Pembrolizumab) in Advanced or Metastatic Malignancy
Lyvgen Biopharma Holdings Limited
Phase 1 Active not recruiting